

1614



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Serial No.: 09/717,746
Filing Date: 11/21/2000
Applicants: Herbert M. Dean et al.
Title: CARDIOPROTECTIVE DOSAGE UNITS
Art Unit: 1614
Examiner: Donna A. Jagoe

RECEIVED

MAY 15 2002

Commissioner for Patents
Washington, DC 20231

COPY OF PAPERS
ORIGINALLY FILED

TECH CENTER 1600/2900

Dear Sir:

Enclosed for filling in the above-referenced patent application please find an Amendment and Request for Reconsideration Pursuant to 37 CFR §1.111 and a return postcard.

Respectfully submitted,

Dated: 4/30/02

Robert R. Deleault, Esq.
Reg. No. 39,165
Attorney for Applicants
41 Brook Street
Manchester, NH 03104
Tel. (603) 668-1971

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on:

April 30, 2002
Robert R. Deleault
Robert R. Deleault



COPY OF PAPERS
ORIGINALLY FILED

THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Serial No.: 09/717,746
Filing Date: 11/21/2000
Applicants: Herbert M. Dean et al.
Title: CARDIOPROTECTIVE DOSAGE UNITS
Art Unit: 1614
Examiner: Donna A. Jagoe

Paper No. _____

RECEIVED

AMENDMENT AND REQUEST FOR RECONSIDERATION
PURSUANT TO 37 CFR § 1.111

TECHNICAL CENTER 1600 2900

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants respectfully request that the following amendments to the Application
be entered:

IN THE CLAIMS:

Please cancel claims 8 and 12.

Please substitute the following claims for the like numbered claims in the application:

1. A medicament dosage unit consisting essentially of a beta-adrenergic blocker and a platelet inhibitor.
7. The dosage unit of Claim 1 wherein said beta-adrenergic blocker is metoprolol.
9. A method of treating cardiovascular disease, said method comprising:
formulating a single dosage unit consisting essentially of a beta-adrenergic